Skip to main content
Equibles
ACRS logo

ACRS · Aclaris Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track ACRS — free

Use ACRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.80 +0.01 (+0.13%) Q1 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$557.88M
Shares
147.20M
Volume · Oct 28 1.07M Avg daily vol (3M) 2.85M

Aclaris Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Aclaris Therapeutics, Inc. (ACRS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-27
Aclaris Therapeutics, Inc. (ACRS) Q3 2026 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Aclaris Therapeutics, Inc. (ACRS) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Aclaris Therapeutics, Inc. (ACRS) Q1 2026 Earnings Call
Revenue
$2.00M
▲ 37.2% YoY
Diluted EPS
$-0.15
Gross margin
80.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-14
Aclaris Therapeutics, Inc. (ACRS) April 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-01-06
Aclaris Therapeutics, Inc. (ACRS) Q4 2025 Earnings Call
Revenue
$1.29M*
▼ 85.9% YoY
Gross margin
58.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q1
2024-05-07
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Positive tone ATI-2138 clinical positioning Atopic dermatitis market opportunity Differentiation from ritlecitinib
Revenue
$2.40M
▼ 5.1% YoY
Diluted EPS
$-0.24
Gross margin
66.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript
Revenue
$2.53M
▲ 74% YoY
Diluted EPS
$-0.42
Gross margin
68.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Aclaris Therapeutics, Inc. (ACRS) Q4 2019 Earnings Call
Revenue
$1.09M*
▼ 70.2% YoY
Gross margin
6.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–8 of 8 webcasts
Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 26 filings 21 filers Visit website Investor relations